A documentary of country legend Glen Campbell's life and “Goodbye Tour” following his diagnosis of Alzheimer's ...

Species: Mouse Genes: MAPT Mutations: MAPT P301L Modification: MAPT: Transgenic Disease Relevance: Alzheimer's Disease, Frontotemporal Dementia Strain Name: Thy1-hTau.P301L Genetic Background: FVB/N ...

Missense mutations in LRRK2 were first identified as a cause of Parkinson’s disease (PD) in 2004. Subsequent studies showed that these mutations account for up to 10 percent of familial cases, with ...

Overview. Pathogenicity: Alzheimer's Disease : Pathogenic, Cerebral Amyloid Angiopathy, Down's Syndrome ACMG/AMP Pathogenicity Criteria: PS1, PS2, PS3, PS4, PM1 Clinical Phenotype Studied: Alzheimer's ...

Dennis Selkoe Co-Director, Brigham and Women's Hospital's Ann Romney Center for Neurologic Diseases; Posted: 21 Mar 2019 This morning’s news that an interim analysis by Biogen of their Phase 3 ...

20 Jan 2022. After months of uncertainty, the hammer fell for Biogen: In a draft decision released January 11, the Centers for Medicare and Medicaid Services proposed to cover the anti-amyloid ...

22 Jul 2022. The Alzheimer’s field was rocked this week by allegations against Sylvain Lesné at the University of Minnesota, Minneapolis. Lesné stands accused of manipulating data images in multiple ...

It has been clear for a while that anti-amyloid antibodies can sweep plaque from the brain, but until now the question of whether this slows cognitive decline has remained hotly contended. Despite ...

04 May 2023. Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

28 Sep 2022. Eisai and Biogen yesterday announced positive topline results from the Phase 3 Clarity trial of their anti-amyloid antibody lecanemab.The drug slowed decline on the primary endpoint, ...

17 Aug 2018. After years of fits and starts, anti-amyloid immunotherapies are finally hitting their target effectively. At least four drugs have now demonstrated the ability to clear plaques from the ...